Abstract:Background: CAR T-cell therapy has been recently unveiled as one of the most promising cancer therapies in hematological malignancies. However, solid tumors mount a profound line of defense to escape immunosurveillance by CAR T-cells. Among them, cytokines with an inhibitory impact on the immune system such as IL-10 and TGFβ are of great importance: TGFβ is a pleiotropic cytokine, which potently suppresses the immune system and is secreted by a couple of TME resident and tumor cells. Methods: In this study, we hypothesized that knocking out the TGFβ receptor II gene, could improve CAR T-cell functions in vitro and in vivo. Hereby, we used the CRISPR/Cas9 system, to knockout the TGFβRII gene in T-cells and could monitor the efficient gene knock out by genome analysis techniques. Next, Mesothelin or Claudin 6 specific CAR constructs were overexpressed via IVT-RNA electroporation or retroviral transduction and the poly-functionality of these TGFβRII KO CAR T-cells in terms of proliferation, cytokine secretion and cytotoxicity were assessed and compared with parental CAR T-cells. Results: Our experiments demonstrated that TGFβRII KO CAR T-cells fully retained their capabilities in killing tumor antigen positive target cells and more intriguingly, could resist the anti-proliferative effect of exogenous TGFβ in vitro outperforming wild type CAR T-cells. Noteworthy, no antigen or growth factor-independent proliferation of these TGFβRII KO CAR T-cells has been recorded. TGFβRII KO CAR T-cells also resisted the suppressive effect of induced regulatory T-cells in vitro to a larger extent. Repetitive antigen stimulation demonstrated that these TGFβRII KO CAR T-cells will experience less activation induced exhaustion in comparison to the WT counterpart. Conclusion: The TGFβRII KO approach may become an indispensable tool in immunotherapy of solid tumors, as it may surmount one of the key negative regulatory signaling pathways in T-cells.

A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies.

Enhancing T Cell Anti-Tumor Efficacy with a PD1-TIGIT Chimeric Immune-Checkpoint Switch Receptor

TIGIT in cancer immunotherapy

TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy

Communication deviances and clarity among the mothers of normally achieving and learning-disabled boys.

Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy

Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

[Patients depending on interpreters require more resources].

CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro

Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors

TIGIT as an emerging immune checkpoint

TIGIT Blockade Prevents CTL and NK Cell Exhaustion and Leads to Tumor Rejection in Mice

Targeting TIGIT for cancer immunotherapy: recent advances and future directions

Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism

TIGIT, a novel immune checkpoint therapy for melanoma